The launch of this new product follows the company's acquisition of AmpTec, a Hamburg, Germany-based mRNA contract development and manufacturing organization.
The company in February announced the extension of its strategic partnership with BioNTech to accelerate the supply of lipids and increase quantities to be delivered toward the end of 2021. The lipids will be used for the production of the Pfizer-BioNTech COVID-19 vaccine.
Filling of MilliporeSigma's new synthetic cholesterol product at the company's Darmstadt, Germany facility. Image courtesy of MilliporeSigma.